Compare CART & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CART | QGEN |
|---|---|---|
| Founded | 2012 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 10.2B |
| IPO Year | 2023 | 1996 |
| Metric | CART | QGEN |
|---|---|---|
| Price | $37.87 | $53.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 7 |
| Target Price | ★ $53.17 | $48.84 |
| AVG Volume (30 Days) | ★ 5.1M | 2.9M |
| Earning Date | 02-12-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 4.45% |
| EPS Growth | 18.25 | ★ 331.25 |
| EPS | 1.81 | ★ 1.94 |
| Revenue | ★ $3,633,000,000.00 | $2,070,781,000.00 |
| Revenue This Year | $12.34 | $7.12 |
| Revenue Next Year | $9.57 | $5.95 |
| P/E Ratio | ★ $20.93 | $28.01 |
| Revenue Growth | ★ 10.16 | 5.32 |
| 52 Week Low | $34.78 | $39.61 |
| 52 Week High | $53.50 | $57.82 |
| Indicator | CART | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 65.39 |
| Support Level | $36.84 | $53.44 |
| Resistance Level | $40.83 | $56.19 |
| Average True Range (ATR) | 1.67 | 2.14 |
| MACD | -0.35 | 0.54 |
| Stochastic Oscillator | 13.25 | 64.03 |
Maplebear (Instacart) is a grocery-focused delivery marketplace that connects national and regional grocers with consumers and couriers, and consumers with their favorite stores. Its app provides on-demand convenience for consumers, allows couriers to earn income, and helps grocers to scale their business through digital channels. The marketplace gathers valuable consumer behavior data, attracting consumer-packaged-goods advertisers that seek to reach consumers at the point of purchase. With approximately 600,000 shoppers and 1,800 retail partners, Instacart delivers to about 98% of households in the United States and Canada.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).